We are live on ! Find out more
SMV

Sofinnova Management VIII Portfolio holdings

AUM $183M
1-Year Est. Return 4.18%
This Fund
S&P 500
This Quarter Est. Return
-1.73%
1 Year Est. Return
+4.18%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$178M
AUM Growth
-$11.2M
Cap. Flow
-$918K
Cap. Flow %
-0.51%
Top 10 Hldgs %
100%
Holding
10
New
–
Increased
–
Reduced
1
Closed
1

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
SPHS
Sophiris Bio, Inc.
SPHS
+$566K
2
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$352K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACRS icon
1
Aclaris Therapeutics
ACRS
$842M
$41.8M 23.4%
1,539,480
– –
ONCE
2
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$41.4M 23.2%
693,128
-6,302
-0.9% -$352K
OBSV
3
DELISTED
ObsEva SA Ordinary Shares
OBSV
$32.1M 17.97%
3,749,623
– –
ARAV
4
DELISTED
Aravive, Inc. Common Stock
ARAV
$27.3M 15.29%
260,543
– –
NTRA icon
5
Natera
NTRA
$44.8B
$16.8M 9.44%
1,550,280
– –
CYTO
6
DELISTED
Altamira Therapeutics Ltd
CYTO
$5.63M 3.15%
98
– –
SYBX
7
DELISTED
Synlogic
SYBX
$4.97M 2.78%
28,332
– –
INNL
8
DELISTED
Innocoll Holdings plc Ordinary Shares
INNL
$4.79M 2.69%
2,103,173
– –
OCGN icon
9
Ocugen
OCGN
$451M
$3.72M 2.08%
34,617
– –
SPHS
10
DELISTED
Sophiris Bio, Inc.
SPHS
– –
-200,000
Closed -$566K

Similar funds

BIC
Bridges Investment Counsel Omaha, Nebraska $181M AUM 21.67% 1-Year Est. Return
CCM
CrestPoint Capital Management Four Seasons, Missouri $180M AUM 21.37% 1-Year Est. Return
YP
Yellowstone Partners Idaho Falls, Idaho $177M AUM
EI
Elkhorn Investments Chicago, Illinois $191M AUM 17.81% 1-Year Est. Return
W
WealthShield Cary, North Carolina $164M AUM
IA
IPL Advisers New York $158M AUM 18.16% 1-Year Est. Return
WI
Welch Investments Birmingham, Alabama $157M AUM 17.66% 1-Year Est. Return
TCM
Texan Capital Management Houston, Texas $154M AUM 98.25% 1-Year Est. Return

Sofinnova Management VIII's Q2 2017 Portfolio in Review

As of Q2 2017, Sofinnova Management VIII held 10 positions worth $178M, down 5.9% from $190M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Sofinnova Management VIII's Q2 2017 filing shows 1 reduced and 1 closed positions. The largest sale was Sophiris Bio, Inc., an estimated $566K.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Sofinnova Management VIII's biggest Q2 2017 reduction was Spark Therapeutics, Inc. Common Stock, cutting an estimated $352K.
  • Sofinnova Management VIII fully exited Sophiris Bio, Inc. in Q2 2017, selling an estimated $566K.
  • Sofinnova Management VIII's ten largest holdings make up 100% of its $178M portfolio in Q2 2017.
  • Sofinnova Management VIII opened 0 new positions and closed 1 in Q2 2017.
  • Sofinnova Management VIII's portfolio value fell 5.9% quarter-over-quarter to $178M.

Based on Sofinnova Management VIII's 13F filing for Q2 2017, filed 19 Jul 2017.